8-K: CalciMedica Reports Q1 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica announced its Q1 2025 financial results, highlighting clinical trial progress and corporate developments, with cash runway extending into mid-2026.

Summary

• CalciMedica reported its financial results for the first quarter ended March 31, 2025.
• Enrollment is ongoing in the Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure, with data expected around the end of 2025.
• A post-hoc analysis of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality for Auxora versus placebo.
• The company's cash position is expected to fund operations into mid-2026.
• CalciMedica plans to hold an end-of-Phase 2 meeting with the FDA around the middle of 2025 and expects to be in a position to initiate a Phase 3 program in acute pancreatitis with SIRS around the end of 2025 pending additional funding.
• In January 2025, Alan Glicklich, M.D., was appointed to the Company's Board of Directors.
• On March 5, 2025, CalciMedica announced a credit facility with Avenue Venture Opportunities Fund II, L.P., providing up to $32.5 million.
• Cash, cash equivalents, and short-term investments were $24.6 million as of March 31, 2025.
• Research and development expenses were $4.2 million for the three months ended March 31, 2025, compared to $2.9 million for the three months ended March 31, 2024.
• General and administrative expenses were $2.3 million for the three months ended March 31, 2025, compared to $2.8 million for the three months ended March 31, 2024.
• Net loss was $5.9 million for the quarter ended March 31, 2025, compared to net income of $0.1 million for the quarter ended March 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, it has a solid cash runway, positive clinical data, and secured a credit facility. The forward-looking statements are cautiously optimistic.

Positives

• The company's cash runway extends into mid-2026, providing financial stability.
• The post-hoc analysis of the CARDEA trial showed a significant reduction in mortality for Auxora in AKI patients with COVID-19 pneumonia.
• CalciMedica secured a credit facility providing up to $32.5 million, strengthening its financial position.
• Alan Glicklich, M.D., was appointed to the Company's Board of Directors, bringing significant biotechnology industry experience.

Negatives

• The company reported a net loss of $5.9 million for the quarter ended March 31, 2025, compared to net income of $0.1 million for the quarter ended March 31, 2024.
• Other income decreased by $4.4 million primarily due to a decrease in non-cash gain related to the fair value adjustments to the Company's financial instruments.

Risks

• The company's ability to initiate a Phase 3 program in acute pancreatitis with SIRS around the end of 2025 is pending additional funding.
• The forward-looking statements are subject to risks and uncertainties, including the impact of fluctuations in global financial markets, the ability to obtain and maintain regulatory approval for Auxora, and potential safety and other complications from Auxora.

Future Outlook

CalciMedica anticipates multiple milestones in 2025, including the Phase 2 KOURAGE trial data readout and an end-of-Phase 2 meeting with the FDA, and expects its cash position to be sufficient to fund its current operating plan into mid-2026.

Management Comments

• We continue to execute across our pipeline and have taken steps to ensure that we are well-positioned ahead of multiple expected milestones in 2025, said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
• Our cash runway extends into mid-2026, which will allow us to deliver the readout of our Phase 2 KOURAGE trial in AKI with respiratory failure expected around the end of this year, as well as to discuss our Phase 3 program in acute pancreatitis with SIRS with the FDA.
• Our lead compound, Auxora, has the potential to transform treatment in both indications, which have no approved therapies and affect hundreds of thousands of critically ill patients per year in the United States and many more worldwide.

Industry Context

CalciMedica is focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases, addressing unmet needs in acute kidney injury and acute pancreatitis, which currently lack approved therapies. The company's focus on these indications positions it to potentially capture a significant market share if Auxora proves successful in clinical trials.

Comparison to Industry Standards

• The 62.7% relative reduction in mortality observed in the post-hoc analysis of the CARDEA trial for AKI patients with COVID-19 pneumonia is a significant result compared to standard care and other investigational therapies in this patient population.
• Companies like Akebia Therapeutics and Ardelyx are also developing therapies for kidney-related diseases, but CalciMedica's focus on CRAC channel inhibition represents a unique approach.
• In the acute pancreatitis space, Omeros Corporation has investigated therapies, but CalciMedica's Auxora targets a different mechanism of action, potentially offering a distinct therapeutic benefit.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the cash runway and clinical progress.
• Employees can be reassured by the company's financial stability and ongoing clinical trials.
• Patients may benefit from the potential approval of Auxora for AKI and AP.
• Creditors are likely to view the credit facility as a positive sign of financial health.

Next Steps

• Continue enrollment in the Phase 2 KOURAGE trial of Auxora in AKI and respiratory failure.
• Deliver the readout of the Phase 2 KOURAGE trial in AKI with respiratory failure expected around the end of this year.
• Hold an end-of-Phase 2 meeting with the FDA around the middle of 2025 for the AP program.
• Initiate a Phase 3 program in acute pancreatitis with SIRS around the end of 2025 pending additional funding.
• File the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the SEC.

Key Dates

Keywords

CalciMedica, Auxora, Acute Kidney Injury, AKI, Acute Pancreatitis, AP, Clinical Trial, Financial Results, KOURAGE, CARDEA, CRAC channel inhibition, Biopharmaceutical